Resveratrol for Aging

Verdict: Doesn't slow aging in humans

Resveratrol has not been shown to slow aging or extend life in people; human trials are null on most outcomes, and high doses may even raise cardiovascular risk markers. The famous longevity findings come from yeast and mice, not humans.

D 🔴 D Counter-Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

This rates as Counter-Evidence because the human data actively fail to support an anti-aging benefit, rather than simply being thin. No clinical trial has ever tested lifespan or a hard aging endpoint. A 2012 cross-species meta-analysis (PMID 22718956) found life extension only in yeast and nematodes, with effects shrinking and turning inconsistent in higher organisms, and its authors warned against extrapolating to people.

Controlled human studies are largely null. A 2021 systematic review and meta-analysis (PMID 33303422) bluntly framed resveratrol as a 'cognitive enhancer for mice only,' finding no significant effect on cognition, mood, grey-matter volume, or blood pressure. A 2024 systematic review (PMID 38433010) found resveratrol alone ineffective across conditions, with benefit appearing only when paired with exercise. More concerning, a double-blind RCT (PMID 31891746) showed 1000 mg/day raised cardiovascular risk biomarkers (sVCAM-1, tPAI-1) in overweight older adults.

Regulators and clinics align with this caution. The US FDA has not authorized any anti-aging health claim and ceased evaluating its GRAS notice at the notifier's request, and EFSA found no cause-and-effect for any resveratrol claim. The Mayo Clinic notes it 'was very helpful for mice' but 'is not the bright, shining star' in humans, while Harvard and the National Institute on Aging position is explicitly against it. Poor oral bioavailability further undercuts the supplement's plausibility.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.38
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Counter-Evidence
Confidence
76%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.29
L11 AI re-checkIndependent read
0.30
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.381
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (0 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Effects and safety of resveratrol supplementation in older adults: A comprehensive systematic review
PMID: 38433010 2024 系統性回顧
Finding: Combined resveratrol+exercise improved muscle function; resveratrol alone ineffective vs placebo for diabetes and peripheral artery disease; high dose (1000 mg) raised CVD biomarkers; no serious adverse events reported.
View on PubMed
Resveratrol: A "miracle" drug in neuropsychiatry or a cognitive enhancer for mice only? A systematic review and meta-analysis
PMID: 33303422 2021 系統性回顧
Finding: No statistically significant effect on cognitive measures, mood, grey matter, or blood pressure in human trials; stark discrepancy from positive animal data.
Academic
View on PubMed
Higher dose of resveratrol elevated cardiovascular disease risk biomarker levels in overweight older adults - A pilot study
PMID: 31891746 2020 RCT (double-blind) n = 29
Finding: 1000 mg/day group showed significantly higher sVCAM-1 and tPAI-1 vs 300 mg and placebo (p<0.05), suggesting high-dose resveratrol may increase CVD risk markers in overweight older adults.
🟠 Limited quality Government Effect size: sVCAM-1 and tPAI-1 significantly elevated vs placebo (p<0.05); no numeric SMD reported
View on PubMed
The effect of resveratrol on longevity across species: a meta-analysis
PMID: 22718956 2012 統合分析 n = 19
Finding: Resveratrol showed life-extending effect in simpler organisms (yeast, nematodes) but diminishing and inconsistent effects in higher-order species; authors cautioned against extrapolation to humans.
🟠 Limited quality Academic Effect size: negative HR point estimates (control died earlier) but high heterogeneity across species
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
At the notifier's request, FDA ceased to evaluate this notice source↗
L4b EU EFSA
Cautious
L4d TW TFDA / 衛福部
Neutral
訂定「以基因改造啤酒酵母(Saccharomyces cerevisiae) EFSC4687菌株發酵生產之食品原料反式白藜蘆醇(trans-resveratrol)之使用限制及標示規定」,並自即日生效。限用於供成人使用之膳食補充品,每日攝取量上限為150毫克。本產品限供成人使用,孕婦及授乳者應避免食用;服用藥物者須諮詢醫師方可使用。 source↗
L5a NIH Office of Dietary Supplements
Cautious
L5b Mayo Clinic
Cautious
Resveratrol was very helpful for mice... you can't translate what we see in mice every time into what might happen to humans, and it hasn't fallen away completely, but it's not the bright, shining star. source↗
L5c Cleveland Clinic
Neutral
L5d Harvard Health
Against
L5e Specialty Society (condition-mapped)
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-aging-INT-resveratrol-001 繁體中文版 →